mariuscomper.uk
Română

Romania statutory drug register · Consolidated 1 April 2026

Romania’s Reimbursed Medicines List

Look up any active substance (DCI), commercial brand box sold in Romania, ATC code, or G/P chronic code across all 1,183 active substances in 1,644 statutory rows.

53 consolidations 2009–2026+347 unique ATCs (+45.1%)33 chronic groups · 9 programs919 dossiers matched to ANMDMR brands
Try real examples:

Seventeen years of Romania’s drug list (2009–2026)

Every dot is one active substance tracked across all 53 official updates of GD 720/2008 from February 2009 (719 DCIs) to 1 April 2026 (1,183 dossiers, 48.8% marked).

01.04.2026
SublistStatutory rate27 Feb 20091 Apr 2026Net change
● A90%155159+4
◆ B50% (90% pensioner ≤ 330 RON ref)216228+12
■ C1100%223359+136
▲ C2100%447704+257
★ C3100%152147-5
◔ D20%030+30
◈ E150%03+3
✦ E2100%014+14

How pharmacy copay works (statutory arithmetic)

Calculate the public fund share versus out-of-pocket spread above the statutory reference price. Non-clinical rule arithmetic only.

Paid by public fund (FNUASS / Ministry)
—
Patient out-of-pocket estimate
—

What is the difference between Sublists A, B, C1, C2, C3, D, E1 and E2?

Sublist A reimburses 90% of the reference price for core outpatient drugs (159 positions). Sublist B covers 50% — rising to 90% for pensioners earning up to 2,020 RON/month on prescriptions up to 330 RON/month — across 228 rows. Section C1 funds 100% of outpatient chronic conditions grouped in G1–G31i (359 rows), C2 covers 100% of national curative health programs P1–P11 up to the settlement price (704 rows), and C3 grants 100% coverage to children aged 0–18, students without income up to age 26, and pregnant or postpartum women (147 rows). Sublist D reimburses 20% (30 rows), while E1 (50%) and E2 (100%) cover ministry-approved vaccines.

Why does a “100% covered” medicine still cost money at the pharmacy?

Because the reimbursement percentage applies to the statutory reference price (the cheapest qualifying generic or benchmark product in that group), not the shelf price of a higher-priced brand box. Patients pay the full retail difference above that reference price unless they switch to a generic priced at or below reference. See brand-versus-generic matches on The name on the box.

What do the stars (*, **, **^1) and ^Ω, ^β, ^# symbols next to a medicine mean?

Between 2009 and 2026, marked positions requiring extra administrative conditions grew from 37.2% to 48.8% (803 rows). One star (*) limits treatment initiation to a specialist doctor, (**) requires a ministry therapeutic protocol, (**^1) pairs protocol oversight with day-hospital or specialty dispensing, (^Ω) covers 139 positions tied to national cost-volume contracts, and (^β) designates outcome-based cost-volume-result agreements.

Who qualifies for the 90% pensioner discount on Sublist B?

Under Emergency Ordinance 105/2024, pensioners whose combined public pension and social allowance do not exceed 2,020 RON per month (regardless of any other income) pay 10% instead of 50% of the reference price for Sublist B medicines (50% FNUASS plus 40% Ministry of Health transfer) on prescriptions priced up to 330 RON/month at reference; prescriptions above 330 RON revert to the standard 50% rate.

How do I find the exact brand boxes sold in Romania for a generic name?

GD 720/2008 lists chemical active substances (INN / DCI), not commercial boxes. Every lookup above cross-references Romania’s official ANMDMR Nomenclator (12 Nov 2026 snapshot: 919 matched active dossiers) and shows dispensing classification (P-RF, P-6L, PR, PS, S, OTC). You can also compare missing medicines, check medicines tested in Romania, or verify referral validity and age-based preventive blood tests.

Why was a previously covered medicine removed or repealed?

Since February 2009, 131 historical active substance dossiers have left the reimbursed list (10 explicitly repealed and 121 withdrawn) — alongside 33 explicit table repeals and two repealed chronic group notes (G10 and G22) still numbered as vacant positions in GD 720/2008 when therapy guidelines shift or marketing authorizations lapse. Inspect the complete list in the Repealed positions ledger below.

Complete statutory directory (1,644 active rows by sublist)

Each sublist opens with its first 25 positions so the page stays quick; expand any section or filter across all 1,644 positions.

● A Sublist A — 90% reimbursement

25 of 159

Core outpatient medicines reimbursed at 90% of the reference price. (90% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
M01AB16#98
✓
Aflamil
B01AA07#10
✓
Sintrom, Trombostop
J05AB01#93
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
B03BB01#16
✓
Acifol
J01MB02#88
✓
—
A05AA02#5
*
Ursofalk, Ursogrix, Ursolith (+1)
P02CA03#133
✓
Albendazol Vim Spectrum, Duador, Eskazole (+2)
M04AA01#103
✓
Alopurinol Arena, Alopurinol Gemax Pharma, Alopurinol Stada (+2)
N05BA12#115
*
Alprazolam Grindeks, Alprazolam Lph, Frontin (+1)
C01EA01#24
**
Alprostadil Remedia 500 µg, Alprostadil Rompharm, Neupedix (+3)
L02BG01#94
✓
—
C01BD01#20
✓
Amiodarona Arena, Amiodarona Hameln, Amiodarona Lph (+1)
N06AA09#120
*
Amitriptilina Arena
C08CA01#41
✓
Almacor, Amlodipina Arena, Amlodipina Gemax Pharma (+6)
J01CA04#71
✓
Amoxicilina Arena, Amoxicilina Atb, Amoxicilina Forte Farmex (+4)
J01CR02#75
✓
Amoksiklav, Amoksiklav Quicktab, Amoxicilina/acid Clavulanic Aptapharma (+7)
C07AB03#37
✓
Atenolol Arena, Atenolol Lph
R03BA01#136
✓
Clenil Jet, Soprobec
J01CE08#73
✓
Moldamin
D07AC01#61
✓
Betaderm, Betametazona Fiterman, Ekarzin
C07AB05#38
✓
Betaxolol Gemax Pharma, Lokren
C07AB07#39
✓
Bisogamma, Bisoprolol Gemax Pharma, Bisotens (+4)
N05BA08#114
*
Bromazepam Arena, Bromazepam Lph, Bromazepam Slavia
R03BA02#137
✓
Cortair, Frenolyn 200 µg, Frenolyn 400 µg (+1)
C09AA01#46
✓
Captopril - Ac, Captopril Arena, Captopril Laropharm (+4)

◆ B Sublist B — 50% reimbursement (90% low-income pensioners)

25 of 228

50% of the reference price (or 90% — 50% FNUASS + 40% Ministry of Health transfer — for pensioners earning ≤ 2,020 RON/month, up to a 330 RON/month reference-price prescription cap). (50% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
M05BA04#146
✓
Adronik, Alendronat Sandoz, Binosto (+2)
D10AX03#78
✓
Skinoren
D06AX01#64
✓
—
M05BA07#147
✓
Actonel, Actonel Saptamanal, Risedronat Arena
A16AX01#11
**^#
Acid Tioctic Gemax Pharma, Acid Tioctic Rompharm, Acid Tioctic Zentiva (+2)
D05BB02#63
**
—
A11CC03#10
✓
Alfacalcidol Gemax Pharma, Alfacalcidol Heaton, Alfacalcidol Stada (+6)
G04CA01#111
✓
Xatral SR
R03DA05#182
✓
Aminofilina Arena, Aminofilina Bioeel, Miofilin
J01CR01#124
✓
Ampicilina/sulbactam Aptapharma, Ampiplus
B01AF02#212
**
Abatixent, Aboxoma, Apixaban Accord (+27)
B01AF02#222
**^#^Ω
Abatixent, Aboxoma, Apixaban Accord (+27)
C10AA05#52
✓
Ascord, Atoris, Atorvastatina Arena (+5)
L04AX01#140
✓
Imuran
J01FA10#129
✓
Azibiot, Azitromicina Arena, Azitromicina Rompharm (+5)
M03BX01#145
^#
Baclofen Sintetica, Lioresal
R03AL09#230
**^#
Trimbow
C09AA07#34
✓
—
N07CA01#167
✓
Betahistina Atb, Betahistina Gemax Pharma, Betahistina Lph (+5)
H02AB01#120
✓
Diprophos
S01BA06#193
✓
—
C10AB02#54
✓
Bezafibrat Arena
N04AA02#153
✓
—
A02BX05#3
✓
—
J05AB15#135
*^#
Brival

■ C1 Sublist C, Section C1 — Chronic disease groups (G1–G31i), 100%

25 of 359

Outpatient medicines reimbursed at 100% of the reference price by coded chronic condition (G1–G31i); specialist initiation required except G1 pos. 2–7, 9 and G10 pos. 15–22. (100% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
L04AA24G31e · #2
**^1
Orencia
L04AA24G31b · #8
**^1
Orencia
D11AH08G31g · #3
**^1^Ω
Cibinqo
B01AA07G1 · #1
✓
Sintrom, Trombostop
B01AA07G2 · #1
✓
Sintrom, Trombostop
A05AA02G6 · #1
✓
Ursofalk, Ursogrix, Ursolith (+1)
N03AG01G15 · #1
✓
Convulex, Depakine, Depakine Chrono (+1)
N03AG01G11 · #5
✓
Convulex, Depakine, Depakine Chrono (+1)
L04AB04G18 · #11
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31a · #2
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31c · #3
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31d · #3
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31e · #3
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31f · #3
**^1
Amgevita, Amsparity, Hefiya (+6)
L04AB04G31b · #4
**^1
Amgevita, Amsparity, Hefiya (+6)
J05AF08G4 · #3
**^1
—
J05AF08G7 · #8
**^1
—
S01LA05G26 · #14
**^Ω
Afqlir, Ahzantive, Baiama (+6)
S01LA05G26 · #20
**
Afqlir, Ahzantive, Baiama (+6)
C10AX14G22 · #15
**^Ω
Praluent
N04BB01G4 · #10
**
Viregyt-k
N04BB01G7 · #15
**
Viregyt-k
N04BB01G12 · #6
**
Viregyt-k
V06DDN1G25 · #11
**
—
N05AL05G15 · #13
**
Masultab, Midora, Solian

▲ C2 Sublist C, Section C2 — National health programs (P1–P11), 100%

25 of 704

Medicines granted under national curative health programs (oncology, diabetes, HIV/hepatitis, rare diseases, transplant), funded 100% up to the settlement price. (100% · settlement price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
J05AF06P1 · #14
✓
Abacavir Aurobindo, Ziagen
J05AR02P1 · #20
✓
Abacavir/lamivudina Mylan, Abacavir/lamivudina Stada, Abacavir/lamivudina Terapia (+1)
L01EF03P3 · #145
**^1
Verzenios
L02BX03P3 · #151
**^1
Abiraterona Dr. Reddy's, Abiraterona Krka, Abiraterona Lannacher (+10)
L01EL02P3 · #173
**^1
Calquence
A10BF01P5 · #22
✓
—
J05AB01P9 · #16
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
J05AB01P9 · #18
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
D06BB03P1 · #33
✓
Acevirex, Aciclovir Fiterman, Aciclovir Rompharm (+4)
J05AB01P1 · #76
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
J05AB01P9 · #8
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
J05AB01P9 · #9
✓
Aciclovir, Aciclovir Accord, Aciclovir Arena (+9)
M05BA04P7 · #15
**
Adronik, Alendronat Sandoz, Binosto (+2)
M05BA04P9 · #29
✓
Adronik, Alendronat Sandoz, Binosto (+2)
M05BA02P3 · #70
**
Sindronat
J01XC01P9 · #12
✓
—
D06AX01P6 · #3
✓
—
J01XC01P6 · #8
✓
—
M05BA06P3 · #72
✓
Acid Ibandronic Accord, Acid Ibandronic Stada, Iasibon (+2)
M05BA03P6 · #1
✓
Pamidronate Hospira
M05BA03P3 · #71
✓
Pamidronate Hospira
J04AA01P1 · #10
^4
—
M05BA07P7 · #16
**
Actonel, Actonel Saptamanal, Risedronat Arena
B02AA02P9 · #3
^4
Acid Tranexamic Kabi, Medsamic, Nimra
B02AA02P9 · #4
^4
Acid Tranexamic Kabi, Medsamic, Nimra

★ C3 Sublist C, Section C3 — Children, pregnant/postpartum women & students (100%)

25 of 147

Additional DCIs reimbursed 100% for children (0–18), eligible students/apprentices (18–26), and pregnant/postpartum women (who also receive A, B, C1, and D drugs at 100%). (100% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
R05CB01#124
✓
Acc Injekt, Fluimucil
A11GA01#18
✓
Acid Ascorbic Arena, Vitamina C Arena, Vitamina C Galenika (+1)
S01AA13#132
✓
Fucithalmic
J01XC01#86
✓
—
S01KA01#142
✓
—
M01AG01#91
✓
Vidan
C10AD02#49
✓
—
M01AX02#93
✓
—
M02AA17#97
✓
—
D07AB10#55
✓
—
C01EA01#38
**
Alprostadil Remedia 500 µg, Alprostadil Rompharm, Neupedix (+3)
A03BA01#3
✓
Sulfat De Atropina Accord, Sulfat De Atropina Evolan, Sulfat De Atropina Noridem
A11DA03#15
✓
Neurossen, Tiavella
P03AX01#117
✓
Benzoat De Benzil Fiterman
A03BB01#4
✓
Bysimin
C05BX01#44
✓
Doxilek, Doxium 500
A12AA03#22
✓
Gluconat De Calciu, Gluconat De Calciu Zentiva
A11CC04#11
✓
Decostriol
B02BX02#27
✓
Adrenostazin
R05CB03#125
✓
Fluidol, Rhinathiol
J01DB04#79
✓
Cefazolina Aptapharma, Cefazolina Atb, Zolinef (+1)
J01DE02#80
✓
—
C07AB08#46
✓
—
S01AA01#131
✓
—
M03BB03#100
✓
Clorzoxazona Arena, Clorzoxazona-richter

◔ D Sublist D — 20% reimbursement

25 of 30

Outpatient medicines reimbursed at 20% of the reference price. (20% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
D06BB03#13
✓
Acevirex, Aciclovir Fiterman, Aciclovir Rompharm (+4)
C10AX06#8
**
Omacor, Tevocor
M09AX01#25
**
Hyalgan
M05BA06#17
*
Acid Ibandronic Accord, Acid Ibandronic Stada, Iasibon (+2)
A11DA03#22
**
Neurossen, Tiavella
H05BA01#14
✓
—
N03AE01#19
✓
Clonazepam G.l. Pharma, Rivotril
C09DB07#28
**
Caramlo, Kandoset, Tilamcar
A11DBN1#23
**
—
C09DA06#30
**
Co-karbis
R03AK14#26
✓
Atectura Breezhaler
C05CA53#12
**
Detralex, Flaxios
A03FA03#7
✓
Domotil
R05CB15#21
**
Erdomed
A02BA03#2
✓
Famodin 20, Famodin 40, Famotidina Zentiva (+2)
A03AA04#5
✓
Colospasmin, Duspatalin
M01AE02#27
✓
Naldorex, Reuxen
C04AE02#10
✓
Nicergolina Lph, Nicergolina Slavia, Sermion (+2)
M01AX17#16
✓
Aulin, Lemesil, Nimesulid Mcc (+2)
C08CA06#29
**
Nimotop
A02BA04#3
✓
—
N06BX03#20
✓
Memotal1 g/5 ml, Nootropil, Piracetam (+9)
M01AC01#15
✓
Flamexin, Piroxicam Arena, Piroxicam Helcor (+3)
A02BA02#1
✓
—
M05BX03#18
✓
—

◈ E1 Sublist E, Section E1 — Vaccines reimbursed 50%

3 of 3

Immunological vaccines (influenza & HPV) reimbursed at 50% of the reference price for population groups defined by Ministry of Health Order (added 1 Sep 2023). (50% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
J07BB02#1
**
Efluelda, Efluelda Tetra, Influvac (+3)
J07BM01#2
**
—
J07BM03#3
**
Gardasil 9

✦ E2 Sublist E, Section E2 — Vaccines reimbursed 100%

14 of 14

Immunological vaccines (flu, HPV, pneumococcal, meningococcal, Tdap, hepatitis B, MMR, varicella) reimbursed at 100% for population groups defined by Ministry of Health Order. (100% · reference price)

Active substance (INN / DCI)ATCGroup / rowMarkersMatched boxes (Romania)
J07AJ52#10
**
Adacel
J07BB02#1
**
Efluelda, Efluelda Tetra, Influvac (+3)
J07BB03#2
**
Fluenz
J07BC01#11
**
Engerix B 10 µg/0,5 ml, Engerix B 20 µg/ml, Euvax B Adult 20 µg/ml (+1)
J07AH08#8
**
Menveo, Nimenrix
J07AH09#9
**
Bexsero, Trumenba
J07BM01#3
**
—
J07BM03#4
**
Gardasil 9
J07AL01#14
**
Pneumovax 23
J07AL02#5
**
—
J07AL02#6
**
—
J07AL02#7
**
—
J07BD52#12
**
M-m-rvaxpro, Priorix, Vaccin Rujeolic-urlian-rubeolic, Viu Atenuat
J07BK01#13
**
Varilrix, vaccin varicelic viu, atenuat, Varivax

Chronic disease groups (G1–G31i) and national programs (P1–P11)

33 outpatient chronic condition groups on Section C1 plus 9 national curative programs on Section C2.

G119 active rows

Chronic heart failure (NYHA class III or IV)

G21 active row

Patients with valvular and vascular prostheses

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea cardiologie, chirurgie cardiovasculară și chirurgie vasculară.

G32 active rows

Percutaneous coronary intervention patients after endovascular stent implantation

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea cardiologie, chirurgie cardiovasculară și chirurgie vasculară.

G416 active rows

Chronic viral hepatitis B, C and D

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea gastroenterologie, boli infecțioase, nefrologie (doar pentru pacienții cu afectare renală consecutivă infecției cu virusuri hepatitice), gastroenterologie pediatrică și pediatrie cu supraspecializare/competență/atestat în gastroenterologie pediatrică.

G53 active rows

Autoimmune hepatitis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea gastroenterologie.

G61 active row

Primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic cirrhosis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea gastroenterologie.

G720 active rows

Liver cirrhosis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea gastroenterologie, boli infecțioase, nefrologie (doar pentru pacienții cu afectare renală consecutivă infecției cu virusuri hepatitice), gastroenterologie pediatrică și pediatrie cu supraspecializare/competență/atestat în gastroenterologie pediatrică, cu excepția DCI-urilor prevăzute la pozițiile 1 și 2, pentru care tratamentul poate fi inițiat și de medicul cu specialitatea medicină internă.

G1028 active rows

Supportive oncology, hematology and pain therapy Note repealed

G1115 active rows

Epilepsy

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea neurologie și neurologie pediatrică.

G1222 active rows

Parkinson's disease and other neurological disorders

G136 active rows

Myasthenia gravis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea neurologie.

G144 active rows

Multiple sclerosis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul din specialitatea neurologie.

G1526 active rows

Psychiatric disorders (schizophrenia, major affective & acute psychotic disorders; pediatric psychiatric conditions, autism, and ADHD)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea psihiatrie și psihiatrie pediatrică/neuropsihiatrie infantilă.

G164 active rows

Dementias (degenerative, vascular, mixed)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea psihiatrie, neurologie sau geriatrie.

G1710 active rows

Major collagenoses (SLE, scleroderma, poly/dermatomyositis, systemic vasculitis)

Statutory initiation rule (RO text)

Tratamentul se inițiază și se monitorizează de către medicul în specialitatea reumatologie, nefrologie, boli infecțioase, pediatrie sau medicină internă, iar pentru medicamentul prevăzut la poziția 6 și de către medicul în specialitatea pneumologie.

G1813 active rows

Rheumatoid arthritis, psoriatic arthritis, severe psoriasis, JIA, Still's, uveitis, hidradenitis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul din specialitatea reumatologie, nefrologie, medicină internă, pediatrie, reabilitare medicală și dermatovenerologie.

G193 active rows

Ankylosing spondylitis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul din specialitatea reumatologie sau reabilitare medicală.

G2232 active rows

Endocrine and metabolic diseases Note repealed

G231 active row

Wilson's disease

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul din specialitatea endocrinologie, neurologie sau neurologie pediatrică.

G2517 active rows

Chronic kidney disease — pre-dialysis stage

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea nefrologie.

G2619 active rows

Chronic ocular diseases (glaucoma, macular, ocular surface & corneal diseases)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea oftalmologie.

G278 active rows

Pemphigus

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea dermatologie.

G294 active rows

Gaucher disease

Statutory initiation rule (RO text)

După precizarea diagnosticului de către laboratoarele de specialitate, tratamentul se inițiază de către medicul din specialitatea gastroenterologie, hematologie, neurologie, neurologie pediatrică și pediatrie.

G309 active rows

Sexually transmitted infections (syphilis, gonorrhea, Chlamydia)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea dermatologie și obstetrică-ginecologie (pentru gonoree și infecția cu Chlamidia).

G31a10 active rows

Inflammatory bowel disease and short bowel syndrome

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea gastroenterologie, gastroenterologie pediatrică și medicină internă.

G31b12 active rows

Rheumatoid arthritis (biological/targeted)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea reumatologie, medicină internă, nefrologie (pentru pacienții cu afectare renală) și reabilitarea medicală.

G31c13 active rows

Psoriatic arthritis (biological/targeted)

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea reumatologie și reabilitare medicală.

G31d9 active rows

Axial spondyloarthritis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea reumatologie, medicină internă și reabilitare medicală.

G31e6 active rows

Juvenile arthritis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea reumatologie, pediatrie și reabilitare medicală.

G31f13 active rows

Severe chronic plaque psoriasis

Statutory initiation rule (RO text)

Tratamentul se inițiază de către medicul în specialitatea dermatologie.

G31g4 active rows

Atopic dermatitis and rare dermatological conditions

G31h7 active rows

Chronic pulmonary diseases

G31i2 active rows

Autoinflammatory periodic fever syndromes

P1142 active rows

National communicable diseases program (HIV/AIDS, TB, hepatitis, etc.)

Program subprograms (RO names) (5)
  • A. Subprogramul de tratament și monitorizare a persoanelor cu infecție HIV/SIDA și tratamentul postexpunere
  • Medicație specifică antiretrovirală
  • Medicație antiinfecțioasă pentru tratamentul infecțiilor asociate
  • B. Subprogramul de tratament al bolnavilor cu tuberculoză
  • C. Subprogramul de supraveghere și control al bolilor transmisibile prioritare - Prevenirea și tratamentul gripei
P3204 active rows

National oncology program

P416 active rows

National neurological diseases program

Program subprograms (RO names) (1)
  • Subprogramul de tratament al sclerozei multiple
P546 active rows

National diabetes program

Program subprograms (RO names) (1)
  • Tratamentul medicamentos al bolnavilor cu diabet zaharat
P696 active rows

National rare diseases, hemophilia, thalassemia & severe sepsis program

Program subprograms (RO names) (34)
  • P6.1: Hemofilie și talasemie
  • P6.2: Epidermoliza buloasă
  • P6.3: Hipertensiunea pulmonară
  • P6.4: Mucoviscidoză
  • P6.5: Boli neurologice degenerative/inflamator-imune
  • P6.5.1 Tratamentul medicamentos al bolnavilor cu boli neurologice inflamator-imune
  • P6.5.2 Tratamentul medicamentos al bolnavilor cu boli neurologice degenerative - scleroză laterală amiotrofică
  • P6.5.3 Tratamentul medicamentos al bolnavilor cu amiloidoză cu transtiretină
  • P6.6: Osteogeneză imperfectă
  • P6.7: Sindrom Prader Willi
  • P6.8: Boala Fabry
  • P6.9: Boala Pompe
  • P6.10: Tirozinemie
  • P6.11: Sepsis sever
  • P6.12: Mucopolizaharidoză tip II (Sindrom Hunter)
  • P6.13: Mucopolizaharidoză tip I (Sindrom Hurler)
  • P6.14: Afibrinogenemie congenitală
  • P6.15: Sindrom de imunodeficiență primară
  • P6.16: Scleroza sistemică și ulcere digitale evolutive
  • P6.17: Purpura trombocitopenică imună idiopatică cronică
  • P6.18: Pacienți adulți și copii cu hiperfenilalaninemie diagnosticați cu fenilcetonurie sau deficit de tetrahidrobiopterină (BH4)
  • P6.19: Scleroză tuberoasă
  • P6.20: Fibroza pulmonară idiopatică
  • P6.21: Distrofia musculară Duchenne
  • P6.22: Angioedem ereditar
  • P6.23: Neuropatia optică ereditară Leber
  • P6.24. Amiotrofia spinală musculară
  • P6.25. Boala Castelman
  • P6.26: Mucopolizaharidoza Tip IVA
  • P6.27: Boli rare - medicamente incluse condiționat
  • P6.28: Limfangioleiomiomatoză
  • P6.29 Lipofuscinoza Ceroidă tip 2 (Deficit de tripeptidil peptidaza - TPP1)
  • P6.30: Sindrom hemolitic uremic atipic (SHU atipic) și hemoglobinurie paroxistică nocturnă (HPN)
  • P6.31: Sfingomielinază acidă (DSMA)
P719 active rows

National endocrine diseases program

Program subprograms (RO names) (1)
  • Tratamentul medicamentos al bolnavilor cu osteoporoză, gușă datorată carenței de iod și proliferării maligne
P9158 active rows

National organ, tissue and cell transplantation program

Program subprograms (RO names) (8)
  • P9.1: Transplant medular
  • P9.2: Transplant de cord
  • P9.3: Transplant hepatic
  • P9.4: Transplant renal, transplant combinat de rinichi și pancreas
  • P9.5: Transplant de celule [orig.: ellule] pancreatice
  • P9.6: Transplant pulmonar
  • P9.7: Tratamentul stării posttransplant în ambulatoriu al pacienților transplantați
  • P9.8: Tratamentul recidivei hepatitei cronice VHB la pacienții cu transplant hepatic
P1019 active rows

National renal replacement therapy (Dialysis) program

P114 active rows

National mental health program

Program subprograms (RO names) (2)
  • P11.1: Subprogramul tratamentul toxicodependențelor
  • P11.2: Tulburare depresivă majoră

Removed and repealed positions (33 table rows + 2 notes)

Vacated rows preserved verbatim inside GD 720/2008, reconciled to their last active molecule in earlier consolidations.

Sublist / group / rowPrior substance (DCI / ATC)Last active dateRepealing act
A · — · #148Omalizumabum (R03DX05)1 April 2022Repealed.
A · — · #149Benralizumabum (R03DX10)1 February 2022Repealed.
B · — · #116Somatropinum (H01AC01)1 February 2022Repealed.
B · — · #221Rivaroxabanum (B01AF01)1 December 2025GD no. 121/2026
B · — · #225Dabigatranum etexilatum (B01AE07)1 January 2024GD no. 397/2024
C1 · G4 · #12Combinații (ombitasvirum + paritaprevirum + ritonavirum) (J05AP53)1 January 2024GD no. 397/2024
C1 · G4 · #13Dasabuvirum (J05AP09)1 January 2024GD no. 397/2024
C1 · G4 · #14Combinații (Ledipasvirum + Sofosbuvirum) (J05AP51)1 November 2024GD no. 1.012/2025
C1 · G6 · #2Acid obeticholicum (A05AA04)1 November 2024GD no. 1.012/2025
C1 · G7 · #16Combinații (ombitasvirum + paritaprevirum + ritonavirum) (J05AP53)1 January 2024GD no. 397/2024
C1 · G7 · #17Dasabuvirum (J05AP09)1 January 2024GD no. 397/2024
C1 · G7 · #18Combinații (Ledipasvirum Sofosbuvirum) (J05AP51)1 November 2024GD no. 1.012/2025
C1 · G10 · #28Pancreatinum (A09AA02)1 February 2021Repealed. ă
C1 · G26 · #15Tafluprostum (S01EE05)1 November 2024GD no. 1.012/2025
C2 · P1 · #83Palivizumabum (J06BB16)1 January 2022Repealed.
C2 · P1 · #106Combinații (Dolutegravirum + Abacavirum + Lamivudinum) (J05AR13)1 December 2025GD no. 121/2026
C2 · P3 · #83Ofatumumab (L01XC10)1 April 2022Repealed. ă
C2 · P3 · #84Dasatinibum (L01XE06)1 June 2021Repealed. ă
C2 · P3 · #88Pazopanibum (L01EX03)2 September 2024Repealed. ă
C2 · P3 · #91Abirateronum (L02BX03)1 January 2024Repealed. ă
C2 · P3 · #124Bevacizumabum (L01XC07)1 February 2021Repealed. ă
C2 · P3 · #133Midostaurinum (L01XE39)1 February 2022Repealed.
C2 · P3 · #148Lenalidomidum (L04AX04)1 February 2021Repealed. ă
C2 · P3 · #150Ruxolitinibum (L01XE18)1 February 2021Repealed. ă
C2 · P5 · #27Benfotiaminum (A11DA03)1 January 2022Repealed.

Repealed chronic group notes (2)

  • Repealed. (effective 01-12-2022, Footnote of chronic group G10 was repealed by Letter c), Point 3, Article I of Government Decision No. 1.346 of 2 November 2022, published in Official Gazette No. 1069 of 03 November 2022 )
  • Repealed. (effective 01-02-2022, Footnote of chronic group G22 Section C1 of the Annex was repealed by Point g), Point 5, Article I of Government Decision No. 24 of 5 January 2022, published in Official Gazette No. 23 of 07 January 2022 )

Method, statutory currency and sources

All statutory counts, sublists, G/P chronic codes, and access symbols come directly from all 53 official XML/HTML consolidations of Hotărârea Guvernului nr. 720/2008 between 27 February 2009 (consolidation 103120) and 1 April 2026 (consolidation 307681, amended by Government Decision No. 121 of 5 March 2026 (Official Gazette No. 181 of 9 March 2026, in force since 1 April 2026)).

Commercial boxes and dispensing classifications (P-RF, P-6L, PR, PS, S, OTC) are matched against Romania’s official ANMDMR Nomenclator snapshot (32,857 rows, updated 12 Nov 2026; 919 matched active dossiers).

Verification currency note: On 14 November 2026, direct automated checks against legislatie.just.ro closed automated connections without responding; independent checks via Wayback Archive (14 July 2026 snapshot), Ministry of Health registers, and CNAS Order 1941/30.10.2026 (valid 1 Nov 2026; all 31 oncology/C2 ATCs verified present in consolidation 307681) confirm no post-1 April 2026 Government Decision consolidation has entered force.

Baseline count reconciliation: Strict 7-character ATC pattern matching on the February 2009 file yields 1,153 rows (768 unique ATCs), matching our sibling Medicines tested in Romania audit; repairing two official table typos and one glued row yields 1,155 standard-ATC rows (769 unique ATCs) and 1,193 active positions total. This site publishes statutory public data only and offers no medical or dosing advice.